Cigarette smoking and interest in quitting in methadone maintenance patients

Nahvi, Shadi; Richter, Kimber P.; Li, Xuan; Modali, Laxmi; Arnsten, Julia H.

doi:10.1016/j.addbeh.2006.01.006

Cited by 110 publications

(141 citation statements)

References 28 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Additional research is needed to determine psychosocial factors associated with quit attempts and successful cessation in this population to guide the design of tailored interventions for various stages of the quitting continuum. While we were not able to find any previous studies examining cigarette smoking quit attempts among IDUs in low-or middle-income countries, a study conducted among methadone maintenance clinic attendees in New York found that 50% of the study participants had made attempts to quit cigarette smoking in the previous year (Nahvi et al, 2006). Similarly, in a study among IDUs recruited from methadone maintenance clinic attendees and needle exchange programs in Providence, RI, 62% reported contemplating quitting cigarette smoking in the next 6 months (Clarke et al, 2001).…”

Section: Discussioncontrasting

confidence: 39%

“…Previous studies have also found high rates of cigarette smoking quit attempts among methadone maintenance patients (Nahvi, Richter, Li, Modali, & Arnsten, 2006;Richter, Gibson, Ahluwalia, & Schmelzle, 2001). However, studies investigating cigarette smoking behavior among IDUs have primarily been conducted in urban areas of the United States (Clarke et al, 2001;Harrell, Trenz, Scherer, Pacek, & Latimer, 2012;Marshall et al, 2011;Villanti et al, 2012).…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Cigarette Smoking and Quit Attempts Among Injection Drug Users in Tijuana, Mexico

Shin

Moreno

Rao

et al. 2013

Nicotine & Tobacco Research

View full text Add to dashboard Cite

introduction: Injection drug use and cigarette smoking are major global health concerns. Limited data exist regarding cigarette smoking behavior and quit attempts among injection drug users (IDUs) in low-and middle-income countries to inform the development of cigarette smoking interventions. We conducted a cross-sectional study to describe cigarette smoking behavior and quit attempts among IDUs in Tijuana, Mexico.

show abstract

Section: Discussioncontrasting

confidence: 39%

Section: Introductionmentioning

confidence: 98%

Cigarette Smoking and Quit Attempts Among Injection Drug Users in Tijuana, Mexico

Shin

Moreno

Rao

et al. 2013

Nicotine & Tobacco Research

View full text Add to dashboard Cite

show abstract

“…In all, 77-93% patients under methadone maintenance treatment (MMT) were reported to smoke cigarettes. [1][2][3][4] It has been shown that tobacco consumption is positively correlated with concurrent administration of mu-opioid receptor (MOR) agonists, heroin, methadone and a MOR partial agonist buprenorphine. [5][6][7] In addition, a previous study indicated that an increase in the dose of methadone could be associated with a stronger craving for nicotine in methadone maintenance patients.…”

Section: Introductionmentioning

confidence: 99%

OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study

et al. 2012

View full text Add to dashboard Cite

Majority of the heroin-dependent patients smoke cigarettes. Although it has been reported that the OPRM1 genetic polymorphism is associated with the brain mu-opioid receptor binding potential in cigarette smokers, there is no direct evidence showing the impact of plasma cotinine, a nicotine metabolite, on treatment responses to methadone maintenance treatment (MMT). In this study, we aimed to test the hypothesis that the genetic polymorphisms in the OPRM1 are associated with the methadone treatment responses and the severity of cigarette smoking directly measured by the plasma concentration of cotinine in a Taiwanese MMT cohort. Fifteen OPRM1 single-nucleotide polymorphisms (SNPs) were selected and genotyped on DNA samples of 366 MMT patients. Plasma concentrations of cotinine were measured by cotinine enzyme-linked immunosorbent assay. The plasma cotinine concentration had positive correlation with concentrations of methadone (P ¼ 0.042) and its metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (P ¼ 0.037). Methadone treatment non-responders, defined by a positive urine morphine test, had a higher plasma concentration of cotinine (P ¼ 0.005), but a lower plasma concentration-todose ratio of both R-and S-methadone (P ¼ 0.001 and 0.012, respectively) than the responders. OPRM1 genetic variants, rs1074287, rs6912029, rs1799971, rs12209447, rs510769, rs3798676, rs553202, rs7748401, rs495491, rs10457090, rs589046, rs3778152 and rs563649, were significantly associated with the plasma concentration of cotinine when using recessive model for genotypes (general linear model (GLM), Po0.038; false discovery rate (FDR)o0.035) and additive model for allele types (GLM, Po0.03; FDRo0.049) in association analyses. The G allele carriers of SNP rs1799971 (A118G) on exon 1 of OPRM1 gene had a lower plasma cotinine concentration than the A allele carriers (GLM, P ¼ 0.029). OPRM1 genetic polymorphisms are associated with the plasma concentration of cotinine in a Taiwanese MMT cohort. Carriers with the major allele of SNP rs1799971 had a higher plasma cotinine concentration.

show abstract

“…On any given day, approximately 1 million Americans are in treatment for alcohol and other drug problems. 11 Research in this new field suggests that many substance abuse treatment patients are highly interested in quitting smoking, [12][13][14][15][16][17][18][19][20] that evidence-based treatment achieves long-term quit rates of 5-14%, 13,[21][22][23][24] and that quitting smoking does not threaten abstinence from other drugs of abuse, but might actually promote it. [6][7][8][9] Some substance abuse treatment facilities are beginning to do so.…”

Section: Introductionmentioning

confidence: 99%

Cigarette smoking cessation services in outpatient substance abuse treatment programs in the United States

Friedmann

Jiang

Richter

2008

Journal of Substance Abuse Treatment

114

View full text Add to dashboard Cite

Objective-To estimate the prevalence and determinants of cigarette smoking cessation treatment in U.S. outpatient substance abuse treatment (OSAT) units. Results-Of OSAT programs in the U.S., 41% offer smoking cessation counseling or pharmacotherapy; 38% offer individual/group counseling and 17% provide quit-smoking medication. In multivariate models, hospital affiliation, service breadth, the priority given to physical health, availability of medication to treat addictive problems, assessment of cigarette smoking, and greater perception of the proportion of patients that smoke were associated with delivery of smoking cessation services. Program size and medical staffing also influenced availability of quit-smoking medication. Methods-ProgramConclusions-Of U.S. OSAT programs, two-in-five offer behavioral treatment for smoking cessation, but fewer than one in five provide access to pharmacotherapy. Substance abuse treatment programs that are medically-oriented, provide more comprehensive services, and recognize the burden of tobacco smoking among their patients are more likely to deliver evidencebased smoking cessation services.

show abstract

Cigarette smoking and interest in quitting in methadone maintenance patients

Cited by 110 publications

References 28 publications

Cigarette Smoking and Quit Attempts Among Injection Drug Users in Tijuana, Mexico

Cigarette Smoking and Quit Attempts Among Injection Drug Users in Tijuana, Mexico

OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study

Cigarette smoking cessation services in outpatient substance abuse treatment programs in the United States

Contact Info

Product

Resources

About